Following the recommendations of the authorities for the coronavirus pandemic, SARA Pharm has taken the necessary measures to ensure the continuity of its activity. The current projects are on-going. The laboratory is operational and the necessary precautions have been taken to allow the safe reception of samples. We do not foresee any impact on our activity to date. In the event of an evolution, we will not fail to keep you informed.

October 23rd, 2020

We are pround that the patent application submitted by SARA Pharm Solutions and National Institute of Materials Physics “Procedee de preparare și utilizare ale noilor forme cristaline ale 6-(3-metil-5-nitroimidazol-4-il)sulfanil-9H-purinei.” – original title (in Romanian) (“Processes for the preparation and use of novel crystalline forms of 6-(3-methyl-5-nitroimidazol-4-yl) sulfanyl-9H-purine.”) was recently published with no. 133946 A0 from 30/03/2020:

The invention relates to novel crystalline forms of 6-(3-methyl-5-nitroimidazol-4-yl) sulfanyl-9H-purine used in medicine as an immunosuppressant, in the treatment and prevention of autoimmune diseases, and in organ transplantation in order to reject organ by the host. The present invention describes novel crystalline forms of 6-(3-methyl-5-nitroimidazol-4-yl) sulfanyl-9H-purine as five novel solvated forms (III, IV, V, VI, VII) obtained by simple steps and easy to control, characterization methods and their uses.

This work was supported by the Romanian grant POC 2014-2020, Priority axis 1 – A1.2.3-G, 4529/2017 (AMD-FARMA-MED-RO) carried out in collaboration with National Institute of Materials Physics.